Why the study?
Does intravenous argatroban provide adequate anticoagulation and satisfactory procedural outcomes in patients with heparin-induced thrombocytopenia undergoing PCI?
Does intravenous argatroban provide adequate anticoagulation and satisfactory procedural outcomes in patients with heparin-induced thrombocytopenia undergoing PCI?
Argatroban provides effective and safe alternative anticoagulation for patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
May support argatroban as alternative anticoagulation in HIT patients undergoing PCI; extends observational data but leaves open need for randomized confirmation.
Lewis et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: